Gilead Sciences Updates Passive Stake in Tango Therapeutics

TL;DR

**Gilead still owns Tango stock, signaling continued interest.**

AI Summary

Gilead Sciences, Inc. filed an amended SC 13G/A on February 13, 2024, indicating its ownership of Tango Therapeutics, Inc. common stock as of December 31, 2023. This filing updates previous disclosures, confirming Gilead's continued significant, though passive, stake in Tango Therapeutics. For investors, this means a major pharmaceutical company maintains an interest in Tango, potentially signaling confidence in its long-term prospects or ongoing collaboration, which could influence stock stability.

Why It Matters

This filing confirms Gilead's continued, albeit passive, investment in Tango Therapeutics, which can be seen as a vote of confidence from a major pharmaceutical player, potentially stabilizing Tango's stock.

Risk Assessment

Risk Level: low — This is an amendment to a passive ownership filing, indicating no immediate change in control or significant new risk.

Analyst Insight

Investors should note Gilead's continued passive stake in Tango Therapeutics, which could be a positive signal, but this filing alone doesn't suggest any immediate catalysts or changes in operational strategy for either company.

Key Players & Entities

• Gilead Sciences, Inc. (company) — the reporting person and investor in Tango Therapeutics
• Tango Therapeutics, Inc. (company) — the subject company in which Gilead Sciences holds shares
• December 31, 2023 (date) — the date of the event requiring this filing
• 87583X109 (other) — the CUSIP number for Tango Therapeutics' Common Stock

FAQ

Key Financial Figures

• $0.001 — INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securiti

Filing Documents

• d756953dsc13ga.htm (SC 13G/A) — 42KB
• 0001193125-24-033887.txt ( ) — 44KB

From the Filing

SC 13G/A 1 d756953dsc13ga.htm SC 13G/A SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* TANGO THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 87583X109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 87583X109 1 N AME OF R EPORTING P E RSON Gilead Sciences, Inc. 2 C HECK THE A PPROPRIATE B OX IF A M EMBER OF A G ROUP (S EE I NSTRUCTIONS ) (a)(b) 3 SEC U SE O NLY 4 C ITIZENSHIP OR P LACE OF O RGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5 S OLE V OTING P OWER 4,854,443 6 S HARED V OTING P OWER 0 7 S OLE D ISPOSITIVE P OWER 4,854,443 8 S HARED D ISPOSITIVE P OWER 0 9 A GGREGATE A MOUNT B ENEFICIALLY O WNED BY E ACH R EPORTING P ERSON 4,854,443 10 C HECK IF THE A GGREGATE A MOUNT IN R OW (9) E XCLUDES C ERTAIN S HARES (S EE I NSTRUCTIONS ) 11 P ERCENT OF C LASS R EPRESENTED BY A MOUNT IN R OW (9) 4.8% (1) 12 T YPE OF R EPORTING P ERSON (S EE I NSTRUCTIONS ) CO (1) Percentage based on 101,989,696 shares of Common Stock outstanding as of November 1, 2023, as disclosed in the Issuers Quarterly Report on Form 10-Q (Form 10-Q) filed with the U.S. Securities and Exchange Commission (SEC) on November 8, 2023. Item1. (a) Name of Issuer Tango Therapeutics, Inc. (the Issuer) (b) Address of Issuers Principal Executive Offices 100 Binney St., Suite 700 Cambridge, Massachusetts 02142 Item2. (a) Names of Persons Filing Gilead Sciences, Inc. (b) Address of Principal Business office or, if none, Residence 333 Lakeside Drive Foster (c) Citizenship Delaware (d) Title of Class of Securities Common Stock, $0.001 par value (e) CUSIP Number 87583X109 Item3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8); (e) An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G); (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J); (k) Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J), please specify the type of institution: Item4. (a) Amount beneficially owned: 4,854,443 (b) Percent of class: 4.8% (1) (c) Number of shares as to which Gilead Sciences, Inc. has: (i) Sole power to vote or to direct the vote: 4,854,443 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 4,854,443 (iv) Shared power to dispose or to direct the disposition of: 0 (1) Percentage based on 101,989,696 shares of Common Stock outstanding as of November 1, 2023, as disclosed in the Issuers Form 10-Q filed with the SEC on November 8, 2023.. Item5. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following Item6. N/A Item7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person. N/A Item8. Identification and Classification of Members of the

View Full Filing

View this SC 13G/A filing on SEC EDGAR